DOI: 10.5301/ejo.5000389
Eur J Ophthalmol 2014; 24 ( 3 ): 375-381
Original Article
Efficacy of transscleral diode laser cyclophotocoagulation in patients with good visual acuity Saurabh Ghosh1, Sridhar Manvikar 2, Neeta Ray-Chaudhuri1, Michael Birch1 1 2
Royal Victoria Infirmary, Newcastle - UK The James Cook University Hospital Middlesbrough, Middlesbrough - UK
Purpose: To study the effect on central vision of transscleral diode laser cyclophotocoagulation (TSDLC) for the reduction of intraocular pressure (IOP) in patients with visual acuity (VA) better than 6/18. Methods: Retrospective chart review was conducted of patients undergoing cyclophotocoagulation between 2000 and 2008. Patients who underwent TSDLC with VA of 6/18 or better and at least 24 months follow-up were included. Primary outcome was decrease of 2 or more lines at 24 months. Secondary outcome was IOP control with or without treatment. Results: A total of 46 eyes of 44 patients were included with VA ranging from 6/18 to 6/5 (median VA 6/12). Mean IOP was 24 mm Hg (range 12-35). A mean of 1.3 treatments were given per eye, with 12 eyes (26%) requiring retreatment. At 24 months, the median VA was 6/18 (range light perception–6/5). Eighteen eyes (39.1%) retained the same VA, 35 eyes (76.1%) retained VA of 6/18 or better, in 7 eyes (19.4%) VA was
Eur J Ophthalmol 2014; 24 ( 3 ): 375-381
Original Article
Efficacy of transscleral diode laser cyclophotocoagulation in patients with good visual acuity Saurabh Ghosh1, Sridhar Manvikar 2, Neeta Ray-Chaudhuri1, Michael Birch1 1 2
Royal Victoria Infirmary, Newcastle - UK The James Cook University Hospital Middlesbrough, Middlesbrough - UK
Purpose: To study the effect on central vision of transscleral diode laser cyclophotocoagulation (TSDLC) for the reduction of intraocular pressure (IOP) in patients with visual acuity (VA) better than 6/18. Methods: Retrospective chart review was conducted of patients undergoing cyclophotocoagulation between 2000 and 2008. Patients who underwent TSDLC with VA of 6/18 or better and at least 24 months follow-up were included. Primary outcome was decrease of 2 or more lines at 24 months. Secondary outcome was IOP control with or without treatment. Results: A total of 46 eyes of 44 patients were included with VA ranging from 6/18 to 6/5 (median VA 6/12). Mean IOP was 24 mm Hg (range 12-35). A mean of 1.3 treatments were given per eye, with 12 eyes (26%) requiring retreatment. At 24 months, the median VA was 6/18 (range light perception–6/5). Eighteen eyes (39.1%) retained the same VA, 35 eyes (76.1%) retained VA of 6/18 or better, in 7 eyes (19.4%) VA was
